Federal Circuit Splits Decision in Pfizer v. Sanofi Vaccine Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
Learn from this case
Understand the legal analysis, timeline, and key takeaways
RecommendedCheck my product’s risk
Run FTO analysis for your own technology or product
Explore patent landscape
View related patents and competitive intelligence
📋 Case Summary
| Case Name | Pfizer, Inc. v. Sanofi Pasteur, Inc. (with SK Chemicals Co., Ltd.) |
| Case Number | 19-2224 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia |
| Duration | Aug 2019 – Mar 2024 4 years 7 months |
| Outcome | Split Disposition – Affirmed-in-part, Vacated-in-part, Remanded-in-part |
| Patents at Issue | |
| Technology Area | Immunogenic Conjugate Vaccine Compositions |
Case Overview
The Parties
⚖️ Plaintiff
One of the world’s largest biopharmaceutical companies, with a robust vaccine portfolio that includes conjugate vaccine platforms.
🛡️ Defendant
The vaccines division of Sanofi, a global pharmaceutical leader, joined by South Korean manufacturer SK Chemicals, both competing in the conjugate vaccine market.
The Patent at Issue
This dispute centered on U.S. Patent No. 9,492,559 B2 (Application No. US14/597488), covering immunogenic compositions comprising conjugated capsular saccharide antigens used in vaccine formulations—technology foundational to next-generation vaccine platforms. This patent is critical in modern polysaccharide conjugate vaccines designed to enhance immune response, particularly in vulnerable populations.
Developing a similar vaccine composition?
Check if your technology might infringe this or related patents before clinical trials or launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a split disposition: affirming certain aspects of the lower proceeding’s findings, vacating others, and remanding specific issues for further consideration. A portion of the appeal was dismissed, reflecting the multi-faceted nature of the patentability challenges.
Verdict Cause Analysis
The case was litigated on patentability grounds—specifically an invalidity or cancellation action targeting US9492559B2. This framing indicates that Sanofi Pasteur and SK Chemicals challenged the validity of Pfizer’s patent, likely asserting that the claimed conjugate vaccine compositions were anticipated, obvious, or otherwise unpatentable over prior art.
The Federal Circuit’s mixed ruling—affirming some findings, vacating others—is analytically significant, often signaling legal error, insufficient factual findings, or incorrect application of legal standards in the lower proceedings.
Legal Significance
Decisions involving conjugate vaccine patents at the Federal Circuit carry substantial precedential weight in biopharmaceutical IP. The court’s treatment of patentability standards for biological compositions—particularly those involving saccharide conjugation chemistry—can influence how patent examiners and PTAB judges evaluate related claims across the industry.
The **affirmed-in-part** component of the ruling establishes binding precedent on those specific legal and factual determinations, while the **remanded issues** leave questions open that may ultimately generate a second Federal Circuit appeal—extending the case’s influence on vaccine patent jurisprudence.
Strategic Takeaways
For patent holders, a mixed Federal Circuit outcome in an invalidity proceeding is not necessarily a loss; affirmed claims remain valid and enforceable. For accused infringers, a vacatur-and-remand result signals a viable invalidity pathway but demands persistence. For R&D teams, FTO analysis must account for the unresolved enforceability questions on remanded claims, presenting a live risk factor for product development timelines.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in immunogenic conjugate vaccine development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this biopharma litigation.
- Identify key claim construction nuances from the ruling
- Analyze related patents in conjugate vaccine technology
- Assess competitor IP strategies in biopharma
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own vaccine or biologic technology.
- Input your composition description or technical features
- AI identifies potentially blocking biopharma patents
- Get actionable risk assessment report for your IP team
High Risk Area
Conjugated saccharide antigen compositions
Complex Claim Construction
Continues to be a focus in biopharma IP
Precedential Value
Guidance for future vaccine patentability
✅ Key Takeaways
The Federal Circuit’s split disposition underscores the importance of robust, multi-layered claim drafting in biopharmaceutical patents.
Search related case law →Partial vacatur signals ongoing claim viability—affirmed claims in invalidity proceedings remain enforceable assets.
Explore precedents →Frequently Asked Questions
The case centered on U.S. Patent No. 9,492,559 B2 (Application No. US14/597488), covering immunogenic compositions comprising conjugated capsular saccharide antigens used in vaccine formulations.
The Court of Appeals for the Federal Circuit affirmed in part, vacated in part, and remanded in part the lower proceeding’s patentability findings, with a portion of the appeal also dismissed.
The decision contributes to Federal Circuit jurisprudence on biopharmaceutical patentability standards. The remanded issues leave open questions that may generate further appellate guidance directly relevant to conjugate vaccine IP strategy.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 19-2224
- U.S. Patent and Trademark Office — Patent 9,492,559 B2
- PACER — Public Access to Court Electronic Records
- Cornell Legal Information Institute — Graham v. John Deere Co.
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.